Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × NIH × Atrasentan × Clear all

Phase

Phase 3 1 Phase 1 1

Status

Sponsor Class

INDUSTRY 2 NIH 1 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Cyclophosphamide 101 Radiotherapy 96 Doxorubicin 71 Fluorouracil 68 Vincristine 63 Etoposide 63 Cisplatin 63 Carboplatin 63 Paclitaxel 51 Chemotherapy, Adjuvant 45 Specimen Handling 41 Leucovorin 41 Cytarabine 39 Methotrexate 34 Magnetic Resonance Spectroscopy 34 Dexamethasone 30 Gemcitabine 28 Filgrastim 28 Docetaxel 28 Bevacizumab 28 Taxes 27 Peripheral Blood Stem Cell Transplantation 27 Melphalan 27 Tamoxifen 25 Prednisone 24 Immunoglobulin G 24 Disulfides 24 Daunorubicin 22 Oxaliplatin 21 Ifosfamide 20

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00046943 2011-02-21

Atrasentan in Treating Patients With Prostate Cancer

National Cancer Institute (NCI)

Phase 3 Completed

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡